Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells 30,000 Shares of Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) Director Gilla Kaplan sold 30,000 shares of Tyra Biosciences stock in a transaction dated Thursday, June 12th. The shares were sold at an average price of $10.31, for a total value of $309,300.00. Following the transaction, the director now owns 59,623 shares in the company, valued at $614,713.13. This trade represents a 33.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Gilla Kaplan also recently made the following trade(s):

• On Monday, June 16th, Gilla Kaplan sold 6,814 shares of Tyra Biosciences stock. The stock was sold at an average price of $10.38, for a total transaction of $70,729.32.
• On Friday, June 13th, Gilla Kaplan sold 15,000 shares of Tyra Biosciences stock. The stock was sold at an average price of $10.31, for a total value of $154,650.00.

Tyra Biosciences Price Performance

NASDAQ:TYRA traded down $0.09 on Thursday, hitting $9.50. 157,815 shares of the company's stock were exchanged, compared to its average volume of 279,892. The firm has a 50-day moving average price of $9.70 and a 200-day moving average price of $11.85. The company has a market cap of $504.36 million, a P/E ratio of -5.83 and a beta of 1.07. Tyra Biosciences, Inc. has a 52 week low of $6.42 and a 52 week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.02. On average, research analysts expect that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on TYRA. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of Tyra Biosciences in a research report on Monday, March 31st. Wedbush restated an "outperform" rating and issued a $30.00 target price on shares of Tyra Biosciences in a research note on Friday, March 28th. Finally, Piper Sandler began coverage on Tyra Biosciences in a research report on Wednesday, May 21st. They set an "overweight" rating and a $33.00 price target for the company. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $30.83.

Institutional Investors Weigh In On Tyra Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of TYRA. KLP Kapitalforvaltning AS acquired a new position in Tyra Biosciences in the fourth quarter valued at about $31,000. US Bancorp DE bought a new position in Tyra Biosciences in the 4th quarter valued at about $50,000. BNP Paribas Financial Markets acquired a new position in shares of Tyra Biosciences in the 4th quarter valued at approximately $60,000. Aquatic Capital Management LLC acquired a new position in shares of Tyra Biosciences in the 4th quarter valued at approximately $64,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Tyra Biosciences during the 1st quarter worth approximately $84,000. Institutional investors and hedge funds own 84.14% of the company's stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.